Teladoc Health, Inc.
Close on Oct 19, 2026
- Market cap
- $1.04B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 22, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | After market close | $606.90M | $-0.21 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | After market close | $613.80M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $642.30M | $-0.14 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 23, 2025 | After market close | $626.40M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | After market close | $631.90M | $-0.19 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | After market close | $629.40M | $-0.53 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $640.50M | $-0.28 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | After market close | $640.50M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 5, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | Full Year 2026 | $271.00M to $303.00M | Narrowed |
| Adjusted EBITDAnon-GAAP | 3Q 2026 | $62.00M to $74.00M | New |
| Net loss per shareGAAP | Full Year 2026 | $-1.00 to $-0.75 | Narrowed |
| Net loss per shareGAAP | 3Q 2026 | $-0.30 to $-0.20 | New |
| Free Cash Flownon-GAAP | Full Year 2026 | $130.00M to $170.00M | Maintained |
| U.S. Integrated Care Members | Full Year 2026 | 98.5 to 100.5 | Raised |
| Integrated Care Adjusted EBITDA marginnon-GAAP | Full Year 2026 | 15.6% to 16.4% | New |
| BetterHelp Adjusted EBITDA marginnon-GAAP | Full Year 2026 | 3% to 4.6% | Lowered |
| U.S. Integrated Care Members | 3Q 2026 | 99 to 100.5 | New |
| Integrated Care Adjusted EBITDA marginnon-GAAP | 3Q 2026 | 15.7% to 17.2% | New |
| BetterHelp Adjusted EBITDA marginnon-GAAP | 3Q 2026 | 0.5% to 2.5% | Lowered |
| Integrated Care Revenue growth percentage (year-over-year) | Full Year 2026 | 0.8% to 2.4% growth | Raised |
| BetterHelp Revenue growth percentage (year-over-year) | Full Year 2026 | -19% to -12.7% growth | Lowered |
| Revenue | Full Year 2026 | $2.36B to $2.45B | Lowered |
| Integrated Care Revenue growth percentage (year-over-year) | 3Q 2026 | 0% to 3% growth | New |
| BetterHelp Revenue growth percentage (year-over-year) | 3Q 2026 | -24.2% to -12.3% growth | Lowered |
| Revenue | 3Q 2026 | $569.00M to $609.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Teladoc Health filed with the SEC
Appointment brings seasoned financial leadership as Teladoc Health advances its strategy aimed at delivering disciplined, sustainable growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
“Teladoc Health is uniquely positioned to help healthcare become more connected, intelligent and accessible. I look forward to working with the Board and management team as the company advances innovation and creates long-term value,” said Anquillare.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
(In thousands, except per share data, unaudited)
Results of operations · EX-99.1 to Form 8-K
(In thousands, except per share data, unaudited)
Results of operations · EX-99.1 to Form 8-K
“Integrated, outcomes focused care is central to creating lasting value in healthcare,” said Salka. “Teladoc Health is an innovative leader and I look forward to contributing strategic and operational perspectives on the company’s next phase of growth.”
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
($ in thousands, except per share data, unaudited)
Results of operations · EX-99.1 to Form 8-K
“Teladoc Health’s mission to transform high‑quality care with technology is more important than ever,” said Smith. “I’m pleased to join the Board and bring my experience leading transformational change and sustainable value creation.”
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
($ in thousands, except per share data, unaudited)
Results of operations · EX-99.1 to Form 8-K
Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated Outlook
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
($ in thousands, except per share data, unaudited)
Results of operations · EX-99.1 to Form 8-K
($ in thousands, except per share data, unaudited)
Results of operations · EX-99.1 to Form 8-K
Full Year and Fourth Quarter 2024 Highlights
Results of operations · EX-99.1 to Form 8-K
($ in thousands, except per share data, unaudited)
Results of operations · EX-99.1 to Form 8-K
Financial and Operational Highlights for Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Experienced Healthcare Leader to Head Global Virtual Care Company
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Financial and Operational Highlights for First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
The Board has retained an executive search firm, which will evaluate internal and external candidates to identify Mr. Gorevic’s permanent successor.
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Eric Evans to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
First quarter 2023 revenue grows 11% year-over-year to $629.2 million
Results of operations · EX-99.1 to Form 8-K
Fourth quarter revenue grows 15% year-over-year to $637.7 million and full year revenue grows 18% year-over-year to $2,406.8 million
Results of operations · EX-99.1 to Form 8-K
Enterprise Growth & Global Markets
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Third quarter revenue grows 17% year-over-year to $611.4 million
Results of operations · EX-99.1 to Form 8-K
Second quarter revenue grows 18% year-over-year to $592.4 million.
Results of operations · EX-99.1 to Form 8-K
NY, July 25, 2022 -- Teladoc Health (NYSE: TDOC), the global leader in whole-person
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
First quarter revenue grows 25% year-over-year to $565.4 million
Results of operations · EX-99.1 to Form 8-K
Fourth quarter revenue grows 45% year-over-year to $554.2 million and total visits increase 41% to 4.4 million
Results of operations · EX-99.1 to Form 8-K
This presentation contains, and our officers may make, “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently
Regulation FD disclosure · EX-99.1 to Form 8-K
Third quarter revenue grows 81% year-over-year to $522 million, updating 2021 revenue outlook to $2,015 million to $2,025 million.
Results of operations · EX-99.1 to Form 8-K